First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT) is trading at $16.66 and Stock Options Channel highlights two option strategies: selling a $15 put (bid $0.10) would obligate purchase at $15 with a net cost basis of $14.90, is ~10% out‑of‑the‑money, has a 68% chance to expire worthless, and yields 0.67% (3.86% annualized) if it does. The covered‑call example sells a $17.50 call (bid $0.30) against shares bought at $16.66, representing ~5% upside, a 6.84% total return if called at Feb 2026, a 45% chance to expire worthless, and a 1.80% boost (10.43% annualized). Implied volatilities are elevated (put 130%, call 106%) versus trailing 12‑month volatility of 74%, making these income‑oriented option plays attractive for yield‑seeking investors but with capped upside and significant volatility risk.

Analysis

Market structure: Elevated implied vols (puts 130%, calls 106% vs realized 74%) make option-selling economically attractive; winners include option market makers, exchanges (NDAQ) and disciplined premium sellers who can absorb biotech tail risk, while strictly long speculative biotech holders are disadvantaged by elevated hedging costs. Supply/demand signals show sellers demanding large risk premia for ADPT exposure — implied vol ≈1.76x realized implies market pricing for idiosyncratic binary events rather than steady drift.

Risk assessment: Tail risks are binary trial/regulatory outcomes or equity dilution that can produce >50% moves in days; immediate (days) risk is IV repricing around any press release, short-term (weeks/months) risk is option decay and assignment risk, long-term (quarters) risk is dilution/cash runway. Hidden dependencies: implied skew shows puts richer than calls — market is pricing downside protection and potential insider/corporate action; catalysts include R&D data, earnings, or block trades which could flip IV quickly.

Trade implications: Use cash‑secured put or put‑verticals to harvest elevated put premia while capping downside; for holders, sell Feb‑2026 $17.50 covered calls to boost carry but hedge upside with cheap long calls if conviction on a surge. Relative ideas: long ADPT equity or assigned shares (target basis $14.90) vs short a basket of high‑IV micro‑cap biotechs to neutralize sector beta; prefer selling vol when IV/realized >1.5 with strict risk caps.

Contrarian angles: Consensus underestimates mean reversion of IV — if no binary event within 3–6 months IV should compress toward realized, rewarding sellers; conversely the market may be underpricing the probability of a large adverse trial result. Historical parallels: biotech IV spikes ahead of binary events then crush on neutral/positive results, benefiting disciplined premium sellers. Unintended consequence: aggressive naked premium selling can produce outsized losses on single‑name biotech shocks, so layer protection or verticalize spreads.

Key Decisions for Investors

• Establish a limited-size cash-secured put on ADPT: sell Feb‑2026 $15 put for ~$0.10 (collect $10/share) sizing 0.5–1.0% of portfolio; intended outcome = assigned basis $14.90. Close/roll if ADPT drops >25% or implied vol rises >30% from current level, or cut position if assigned and cash exposure >3% of portfolio.
• If already long ADPT (~$16.66), sell Feb‑2026 $17.50 covered calls at $0.30 to lock a 6.8% upside to expiry (10.4% annualized); simultaneously buy a Feb‑2026 $20 call (~protective upside) sized at 10–20% of the long position to cap opportunity cost if shares gap >20%.
• Prefer put‑vertical instead of naked puts to limit tail risk: sell Feb‑2026 $15 put and buy $12.50 put to cap downside (max loss ≈$2.40/share); target net credit and use for 0.5–1% portfolio exposure if unwilling to be assigned.
• Rotate 1–2% of equity into NDAQ (Nasdaq) over 3–12 months to capture elevated options/exchange fee flow if sector volatility persists; target add if exchange revenues or options ADV show sequential growth >5% QoQ.